Overview

Trial of Rituximab, Bendamustine (RB) for Patients With Follicular Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line

Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
Evaluate the effectiveness of rituximab, bendamustine (r) in terms of complete response and response complete not confirmed.
Phase:
Phase 2
Details
Lead Sponsor:
Grupo Oncológico para el Tratamiento y el Estudio de los Linfomas
Treatments:
Bendamustine Hydrochloride
Rituximab